Literature DB >> 8432457

Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

C F Sier1, H W Verspaget, G Griffioen, S Ganesh, H J Vloedgraven, C B Lamers.   

Abstract

Carcinogenesis in the human colon is associated with a marked increase of urokinase type plasminogen activator and a decrease of tissue type plasminogen activator. This study was performed to determine the concentrations of urokinase type plasminogen activator and tissue type plasminogen activator in normal tissue and carcinomas along the upper part of the gastrointestinal tract. Activity and antigen levels of both activators were determined in homogenates of endoscopically obtained biopsies from normal and carcinomatous tissues. Although the concentrations of tissue type plasminogen activator and urokinase type plasminogen activator in normal squamous epithelium of the oesophagus were low compared with those in columnar epithelium from the stomach, the urokinase type plasminogen activator/tissue type plasminogen activator antigen ratio of the different locations showed hardly any difference. Significant but heterogeneous increases were found in urokinase type plasminogen activator concentrations of biopsy specimens originating from carcinomas of both epithelial cell types. A decrease in tissue type plasminogen activator concentrations, as found in human colon carcinomas, could only be shown in carcinomas of columnar epithelium origin but not in squamous cell carcinomas of the oesophagus. The increase of urokinase type plasminogen activator and urokinase type plasminogen activator/tissue type plasminogen activator antigen ratio and the decrease of tissue type plasminogen activator in the carcinomas did not show a significant correlation with known prognostic determinants as differentiation grade, TNM classification, intestinal metaplasia, inflammation, and ulceration. The heterogeneous increase of urokinase type plasminogen activator in oesophageal and stomach carcinomas, together with the recently described association of urokinase type plasminogen activator in tissue extracts of breast carcinomas with aggressiveness and prognosis, may be relevance to prognostic studies, may be of relevance to prognostic studies in oesophageal and gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432457      PMCID: PMC1374105          DOI: 10.1136/gut.34.1.80

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

Review 1.  Plasminogen activator inhibitors.

Authors:  E D Sprengers; C Kluft
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

2.  Release of proteinases by cultures of human cell lines derived from squamous carcinomas of the tongue and larynx.

Authors:  A Baici; P Sträuli
Journal:  Exp Cell Biol       Date:  1985

Review 3.  Plasminogen activators, tissue degradation, and cancer.

Authors:  K Danø; P A Andreasen; J Grøndahl-Hansen; P Kristensen; L S Nielsen; L Skriver
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

4.  Increased plasminogen activator inhibition levels in malignancy.

Authors:  E de Jong; E A Knot; D Piket; A H Iburg; D C Rijken; K H Veenhof; G Dooijewaard; J W ten Cate
Journal:  Thromb Haemost       Date:  1987-04-07       Impact factor: 5.249

Review 5.  The relevance of plasminogen activators to neoplastic growth. A review of recent literature.

Authors:  G Markus
Journal:  Enzyme       Date:  1988

6.  Plasminogen activator profiles in neoplastic tissues of the human colon.

Authors:  P A de Bruin; G Griffioen; H W Verspaget; J H Verheijen; G Dooijewaard; H F van den Ingh; C B Lamers
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

7.  The urokinase type of plasminogen activator in cancer of digestive tracts.

Authors:  N Nishino; K Aoki; Y Tokura; S Sakaguchi; Y Takada; A Takada
Journal:  Thromb Res       Date:  1988-05-15       Impact factor: 3.944

8.  Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.

Authors:  K Huber; J Wojta; J C Kirchheimer; D Ermler; B R Binder
Journal:  Eur J Clin Invest       Date:  1988-12       Impact factor: 4.686

9.  Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix.

Authors:  G Larsson; A Larsson; B Astedt
Journal:  Thromb Haemost       Date:  1987-10-28       Impact factor: 5.249

10.  Tissue-type plasminogen activator, a new prognostic marker in breast cancer.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H R Lijnen
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

View more
  17 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.

Authors:  Gabriel Scicolone; Viviana Sanchez; Liliana Vauthay; Federico Fuentes; Alejandro Scicolone; Lorenzo Scicolone; Melina Rapacioli; Vladimir Flores
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

3.  Plasminogen binding and activation at the surface of Helicobacter pylori CCUG 17874.

Authors:  M Pantzar; A Ljungh; T Wadström
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

4.  Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

Authors:  D Morrissey; J O'Connell; D Lynch; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

5.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

6.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

7.  Gastric mucosal plasminogen activators in Helicobacter pylori infection.

Authors:  J M Götz; Y Vergouwe; H W Verspaget; I Biemond; C F Sier; C B Lamers; R A Veenendaal
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

8.  Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro.

Authors:  H Li; H Shimura; Y Aoki; K Date; K Matsumoto; T Nakamura; M Tanaka
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

9.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Authors:  H Allgayer; R Babic; K U Grützner; B C Beyer; A Tarabichi; F W Schildberg; M M Heiss
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

Review 10.  The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?

Authors:  Heike Allgayer; Julio A Aguirre-Ghiso
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.